CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $38 | $17 | $194 | $206 |
| Short-Term Investments | $63 | $157 | $0 | $100 |
| Receivables | $3 | $3 | $36 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $5 | $7 | $4 |
| Total Curr. Assets | $107 | $183 | $237 | $310 |
| Property Plant & Equip (Net) | $11 | $16 | $21 | $25 |
| Goodwill | $1 | $1 | $1 | $1 |
| Intangibles | $1 | $1 | $1 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $2 |
| Total NC Assets | $13 | $19 | $24 | $29 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $121 | $202 | $261 | $339 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $3 | $3 |
| Short-Term Debt | $5 | $5 | $4 | $4 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $67 | $132 | $121 | $41 |
| Other Curr. Liab. | $12 | $18 | $24 | $31 |
| Total Curr. Liab. | $86 | $156 | $153 | $78 |
| LT Debt | $4 | $9 | $14 | $18 |
| Deferred Rev, NC | $27 | $80 | $180 | $244 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $4 | $4 | $0 | $0 |
| Total NC Liab. | $35 | $93 | $194 | $262 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $9 | $14 | $18 | $22 |
| Total Liabilities | $121 | $249 | $347 | $340 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$692 | -$723 | -$723 | -$624 |
| AOCI | $0 | $0 | $0 | -$0 |
| Other Equity | $691 | $676 | $637 | $623 |
| Total Equity | -$0 | -$47 | -$86 | -$0 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $121 | $202 | $261 | $339 |
| Net Debt | -$29 | -$3 | -$176 | -$184 |